Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Plus Dexamethasone Expanded Access in RRMM
NCT00478777Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Time to Disease Progression up to 827 days. Started Mar 2007; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00478777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478777.